Skip to main content
Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome.
Clinical Epigenetics
  • Eric G Bend
  • Erfan Aref-Eshghi, Western University
  • David B Everman
  • R Curtis Rogers
  • Sara S Cathey
  • Eloise J Prijoles
  • Michael J Lyons
  • Heather Davis
  • Katie Clarkson
  • Karen W Gripp
  • Dong Li
  • Elizabeth Bhoj
  • Elaine Zackai
  • Paul Mark
  • Hakon Hakonarson
  • Laurie A Demmer
  • Michael A Levy, Western University
  • Jennifer Kerkhof, Western University
  • Alan Stuart, Western University
  • David Rodenhiser, Western University
  • Michael J Friez
  • Roger E Stevenson
  • Charles E Schwartz
  • Bekim Sadikovic, Western University
Document Type
Publication Date
URL with Digital Object Identifier

ADNP syndrome is a rare Mendelian disorder characterized by global developmental delay, intellectual disability, and autism. It is caused by truncating mutations in ADNP, which is involved in chromatin regulation. We hypothesized that the disruption of chromatin regulation might result in specific DNA methylation patterns that could be used in the molecular diagnosis of ADNP syndrome.

We identified two distinct and partially opposing genomic DNA methylation episignatures in the peripheral blood samples from 22 patients with ADNP syndrome. The "epi-ADNP-1" episignature included ~ 6000 mostly hypomethylated CpGs, and the "epi-ADNP-2" episignature included ~ 1000 predominantly hypermethylated CpGs. The two signatures correlated with the locations of the ADNP mutations. Epi-ADNP-1 mutations occupy the N- and C-terminus, and epi-ADNP-2 mutations are centered on the nuclear localization signal. The episignatures were enriched for genes involved in neuronal system development and function. A classifier trained on these profiles yielded full sensitivity and specificity in detecting patients with either of the two episignatures. Applying this model to seven patients with uncertain clinical diagnosis enabled reclassification of genetic variants of uncertain significance and assigned new diagnosis when the primary clinical suspicion was not correct. When applied to a large cohort of unresolved patients with developmental delay (N = 1150), the model predicted three additional previously undiagnosed patients to have ADNP syndrome. DNA sequencing of these subjects, wherever available, identified pathogenic mutations within the gene domains predicted by the model.

We describe the first Mendelian condition with two distinct episignatures caused by mutations in a single gene. These highly sensitive and specific DNA methylation episignatures enable diagnosis, screening, and genetic variant classifications in ADNP syndrome.


Also available open access in Clinical Epigenetics at:

Citation Information
Eric G Bend, Erfan Aref-Eshghi, David B Everman, R Curtis Rogers, et al.. "Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome." Clinical Epigenetics Vol. 11 Iss. 1 (2019) p. 64 - 64
Available at: